Krystal Biotech's Upcoming Investor Conferences
Krystal Biotech, Inc. (NASDAQ: KRYS), a forward-thinking biotechnology company known for its pioneering work in genetic medicines, has eagerly announced that its Chairman and CEO Krish S. Krishnan is set to participate in two significant investor conferences shortly.
Details of the Conferences
These conferences are vital opportunities for Krystal Biotech to connect with investors, share insights about the company’s progress, and discuss future plans. The first event, Citi's 2024 Global Healthcare Conference, is scheduled for December 3, 2024. At this event, Krish S. Krishnan will engage in a fireside chat, and attendees can expect dialogue on the innovative research Krystal Biotech is pursuing.
Conference Timing
The fireside chat at the Citi conference is set for 8:45 am ET. Shortly thereafter, on December 4, 2024, Krystal Biotech will participate in the Annual Evercore HealthCONx Conference. This occasion also features Krish S. Krishnan participating in another fireside chat, scheduled for 2:10 pm ET.
Webcasts and Accessibility
Each of these presentations will be available as live webcasts, providing a global platform for investors to engage with Krystal Biotech's vision without needing to travel. The company has made it clear that archived versions of these webcasts will be accessible for a minimum of 30 days after the events via their Investors section on their official website.
About Krystal Biotech
Located in Pittsburgh, Pennsylvania, Krystal Biotech, Inc. (NASDAQ: KRYS) focuses on the discovery, development, and commercialization of genetic medicines aimed at addressing diseases with significant unmet medical needs. The company has developed the first-ever redosable gene therapy, known as VYJUVEK, which recently received FDA approval for treating dystrophic epidermolysis bullosa. This landmark achievement showcases Krystal Biotech’s role as an innovator in the biotechnology sector.
Ongoing Clinical and Preclinical Advances
Krystal Biotech continues to push the boundaries of biotechnology with a substantial pipeline of investigational genetic medicines spanning various therapeutic areas including respiratory, oncology, dermatology, ophthalmology, and aesthetics. With each step forward, the company is keenly aware of its role in transforming patient care and improving quality of life.
Stay Updated with Krystal Biotech
For those interested in following Krystal Biotech’s journey, the company encourages visits to their official website and engaging with them on social media platforms like LinkedIn and X. These channels provide updates on their innovative products, research advancements, and future business opportunities that could reshape the field of genetic medicine.
Contact Information
For more inquiries regarding Krystal Biotech, interested parties can reach out to Stéphane Paquette, who manages investor relations, via email. The commitment to transparency and proactive communication remains a cornerstone of Krystal Biotech’s corporate philosophy.
Frequently Asked Questions
What upcoming events is Krystal Biotech participating in?
Krystal Biotech is participating in Citi's 2024 Global Healthcare Conference and the Annual Evercore HealthCONx Conference.
Who is the CEO of Krystal Biotech?
The CEO of Krystal Biotech is Krish S. Krishnan.
What is VYJUVEK?
VYJUVEK is a groundbreaking redosable gene therapy developed by Krystal Biotech for the treatment of dystrophic epidermolysis bullosa.
Where is Krystal Biotech based?
Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.
How can I follow Krystal Biotech's updates?
You can follow Krystal Biotech on their official website and social media platforms like LinkedIn and X.
